AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Pharmaceutical firm reports loss of $0.08 per share.

Obesity, Fitness & Wellness Week

| September 18, 2004 | COPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2004 SEP 18 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) reported a net loss for the third quarter of fiscal 2004 of $6.6 million, or $0.08 per share, compared with a net loss of $6.0 million, or $0.10 per share for the same period a year ago.

Total operating expenses were $7.3 million in the third fiscal quarter of 2004, compared to $6.4 million in the same period in fiscal 2003. Research and development (R&D) expenses were $5.1 million in the third fiscal quarter of 2004, compared to $4.5 million in the same period a year ago.

Research and development programs accounted for 70% of total operating expenses for the 3 months ended June 30, 2004, and June 30, 2003.

The company's phase III clinical trial of Neurodex for the treatment of pseudobulbar affect in patients with multiple sclerosis and the ongoing Neurodex open-label safety study accounted for approximately 42% of all R&D outlays for the quarter.

The phase I clinical trial of our lead compound for the treatment of allergy and asthma accounted for approximately 20% of total R&D spending. The balance of R&D expenses were for preclinical research on potential treatments for inflammation and atherosclerosis and antibody research programs.

R&D spending is expected to continue at the present rate through this current quarter, our fourth fiscal quarter of 2004, as we proceed to analyze and report the results of the Neurodex phase III clinical trial, continue the open label safety study of Neurodex, prepare for the additional phase I clinical trials of our allergy/asthma drug candidate and continue preclinical research related to inflammation and atherosclerosis.

Revenues for the third quarter of fiscal 2004 were $591,000, compared to $398,000 in the same period a year ago. Revenues in the third quarter of fiscal 2004 included $351,000 in revenues that the company recognized from the sale of Abreva royalty rights to Drug Royalty USA and $222,000 from government research grants.

Related articles from newspapers, magazines, journals, and more
Mosaic Quadruples Fiscal 2008 Fourth Quarter Net Earnings Over Year-Ago Quarter.
Press release article from: PR Newswire July 28, 2008 700+ words
...the same period a year ago. Mosaic's gross margin for the fiscal 2008 fourth quarter...of net sales, a year ago. Fourth quarter...fourth quarter in fiscal 2007. Financial...increase compared with a year ago and a $267 per tonne...third quarter of fiscal 2008. ...
AM Communications Reports Third Quarter Fiscal 2003 Results; Revenues Increase...
Press release article from: PR Newswire February 18, 2003 700+ words
...comparable nine-month period a year ago. Revenues generated from...for the third quarter of fiscal 2003 were $5.2 million...million in the same period a year ago. Operating income was...for the same period in fiscal 2002. Revenues for the...
VALUE MERCHANTS EARNINGS INCREASES 74 PERCENT IN FISCAL 1991; FOURTH QUARTER...
Press release article from: PR Newswire March 26, 1992 700+ words
...INCREASES 74 PERCENT IN FISCAL 1991; FOURTH QUARTER EARNINGS...ARE 60 PERCENT AHEAD OF A YEAR AGO MILWAUKEE, March 26...Inc. (NYSE: VMI) for fiscal 1991, ended Feb. 1...from $5,283,000 a year ago. Per share earnings...
Landec Corporation Reports Third Quarter Fiscal Year 2006 Results; Third...
Press release article from: Business Wire March 28, 2006 700+ words
...the same period a year ago. For the first nine months of fiscal year 2006 revenues...149.1 million a year ago, and gross profits...the same period a year ago. The Company reported...first nine months of fiscal year 2006 of $2...
Sodexho Marriott Services Reports Pro Forma Third Quarter Fiscal 1999 EPS,...
Press release article from: PR Newswire June 24, 1999 700+ words
...51.1 million in the fiscal 1999 third quarter from $44.7 million in the year ago quarter. Corporate expenses...the third quarter of fiscal 1999 included a one...effective tax rate for the fiscal 1999 third quarter was...down from 48.0% a year ago, as a result of the...
Avaya reports fourth fiscal quarter and fiscal 2004 results; Avaya earns 21...
Press release article from: M2 Presswire October 27, 2004 700+ words
...fourth fiscal quarter and fiscal 2004 results; Avaya...diluted share in fourth fiscal quarter; Revenues increase 11 percent from year ago quarter to $1.076...reported net income in the year ago quarter of $66 million...diluted share. Fourth fiscal quarter 2004 ...
Sodexho Marriott Services, Inc. Reports Pro Forma Fiscal 1999 Second Quarter...
Press release article from: PR Newswire March 25, 1999 700+ words
...share for the 1999 fiscal second quarter were...0.12 for the year ago quarter on an average...8 million in the fiscal 1999 second quarter...2 million in the year ago quarter aided by...tax rate for the fiscal 1999 second quarter...down from 48.0% a year ago, as a ...
Continucare Corporation Reports Financial Results for Fourth Quarter and Fiscal...
Press release article from: Business Wire September 18, 2006 700+ words
...diluted share a year ago. Full Year Results For the fiscal year ended June...same period one year ago. Income from operations during fiscal 2006 was $7.9...7 million in the year-ago period. Net income for fiscal 2006 was $5.3...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA